Læknablaðið - 15.01.1994, Blaðsíða 20

10
LÆKNABLAÐIÐ
spurning hvort sjúklingar, sem nota lyfin
við lífsstflstengdum vandamálum, eigi ekki
að greiða stærri hlut í kostnaði lyfjanna en
hinir sem taka þau við vel skilgreindum
sjúkdómum.
ÞAKKIR
Höfundar vilja þakka lyfsölum og
lyfjafræðingum í apótekum fyrir mjög góða
samvinnu við að afla upplýsinga sem þessi
grein byggist á.
SUMMARY
Drugs for peptic ulcer (ACT class A02B) are
extensively used in Iceland, 20 DDD/1000/day,
which is 2-3 times higher than in other
Scandinavian countries. A prescription survey was
carried out during one month in 1991 with the help
of pharmacists who registered all prescriptions
with regard to age and sex of the patient, the
speciality of the prescribing doctor and name,
dose and quantity of the drug. A total of 2021
prescriptions were registered accounting for around
90% of all prescriptions. The prevalence of peptic
ulcer drug use was 1.52% and maximal usage
was in the age group 70-79, 2.91%. H, blockers
accounted for 79%, omeprazole for 17%, and other
drugs for 4%. General practitioners prescribe 65%
of the drugs, gastroenterologists 15% and other
specialists 14%. If the patient himself collected the
drug he was asked to fill out a questionnaire with
regard to the reason for the prescription, previous
prescriptions and investigations. A total of 1131
(56%) questionnaires were received. Only 1%
of the patients did not know the reason for the
prescription. The patients registered that 30% of
the prescriptions were for peptic ulcer, 29% for
heartburn, 21% for gastritis, 9% for dyspepsia and
7% for prevention of side effects of other drugs.
Investigations were done in 67% of the patients,
but 33% received prescription after doctor’s
interview only. It was estimated from the data that
about 40% of the prescriptions were for non-ulcer
dyspepsia.
The results suggest that the extensive use of peptic
ulcer drugs in Iceland is due to excessive use in
non-ulcer dyspepsia.
HEIMILDIR
1. Wyllie JH, Clark CG, Alexander Williams J, et al.
Effect of cimetidine on surgery for duodenal ulcer.
Lancet 1981; i: 1307-8.
2. Baron JH, Alexander Williams J, Beasnell JR.
Cimetidine and duodenal ulcer. Br Med J 1979; 1:
169-73.
3. Bardham KD, Hinchliffe RFC. Effect of cimetidine
on surgery for duodenal ulcer. Lancet 1981; ii: 38.
4. Penn I. The deciining role of the surgeon in the
treatment of acid peptic diseases. Arch Surg 1980;
115: 134-5.
5. Fineberg HV, Pearlmann LA. Surgical treatment of
peptic ulcer in the United States. Trends before and
after the introduction of cimetidine. Lancet 1981; i:
1305-7.
6. Tilvis RS, Vuoristo M, Varis K. Changed profile of
peptic ulcer disease in hospital patients during 1969-
1984 in Finland. Scand J Gastroenterology 1987; 22:
1238-44.
7. Bardham KD, Cust G, Hinchliffe RCF, Williamson
FM, Lyon C, Bose K. Changing pattem of admissions
and operations for duodenal ulcer. Br J Surg 1989;
76: 230-6.
8. Kurala JH, Honda GD, Frantel H. Hospitalization
and mortality rates for peptic ulcer: a comparison
of a large health maintenance organization and
United States data. Gastroenterology 1982; 83: 1008-
16.
9. Makela J, Lattinen J. Kauruloma MI. Complications
of peptic ulcer disease before and after the
introduction of H2 receptor antagonists. Hepato-
Gastroenterology 1992; 39: 144-8.
10. Christensen A, Bousfield R. Ulcuskirurgi för och efter
indförelsen af H, blokker behandlinger. Ugeskr Læger
1987; 149/43: 2895-7.
11. Walt R, Katschinski B, Logan R, Ashley J, Langmann
M. Rising frequency of ulcer perforation in elderly
people in the United Kingdom. Lancet 1986; i: 489-
92.
12. Hansen JM, Bytzer F, Muckadell OB.
Ulcuskomplikationer i Fyns Amt i perioden 1980-
1990. Ugeskr Læger 1991; 153: 1402-5.
13. Koo J, Ngan YK, Lam SK. Trends in hospital
admission, perforation and mortality of peptic ulcer in
Hong Kong from 1970-1980. Gastroenterology 1983;
84: 1558-62.
14. Penston JG, Wormsley KG. Nine years of
maintenance treatment with ranitidine for patients
with duodenal ulcer disease. Aliment Pharmacol Ther
1992; 6: 629-45.
15. Penston JG, Wormsley KG. Trends in morbitidy and
mortality from peptic ulcer disease. Tayside versus
Scotland. Aliment Pharmacology and Therapeutics
1993; 7: 429-42.
16. La Vecchia C, Lucchini F, Negri E, Reggi V, Levi F.
The impact of therapeutic improvements in reducing
peptic ulcer mortality in Europe. Int J Epidemiol
1993; 22: 96-106.
17. Nordic Statistics on Medicines 1987-1989. NLN
Publication 1990; 30: 47.
18. Icelandic drug market. 2Q 1991. Kpbenhavn: Dansk
lægemiddelstatistik, 1991.
19. Thors H, Sigurðsson H, Oddsson E, Þjóðleifsson B.
Aðgerðir við ulcus pepticum á Islandi 1971-1989.
Læknablaðið 1992 / Fylgirit 21: 62. (Ágrip).
20. Thors H. Sigurðsson H. Oddsson E, Þjóðleifsson B.
Dánartíðni af völdum ulcus pepticum á íslandi 1950-
1990. Læknablaðið 1992 / Fylgirit 21: 63. (Ágrip).
21. Dungal N, Hansen H, Schweiz Z. Peptic ulcers in
Iceland. Path Bakt 1958; 21: 225-8.
22. Bonnevie O. Changing demographics of peptic ulcer
disease. Dis Dis Sci 1985; 30 / Suppl. 11: 85-145.
23. Colin Jones DG, Bloom B, Bodemar G. The
management of dyspepsia: Report of a Working
Party. Lancet 1988; i: 576-9.
24. Gudjónsson H, Oddsson E, Bjömsson S, et al.